Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients
Patients with non-small cell lung cancer (NSCLC) have been shown to benefit from the
introduction of anti-PD1 treatment. However, not all patients experience tumor regression and
durable response. The identification of a string of markers that are direct or indirect indicators of
the immune system fitness is needed to choose optimal therapeutic schedules in the management
of NSCLC patients. We analyzed 34 immuno-related molecules (14 soluble immune checkpoints,
17 cytokines/chemokines, 3 adhesion molecules) released in the serum of 22 NSCLC patients under